ABSTRACT
Introduction Adverse childhood experiences (ACEs) are associated with brain alterations and cognitive decline. In later life, cognitive impairment and mild behavioural impairment (MBI) are associated with greater dementia risk.
Objective & Study Design We investigated whether more severe ACEs are cross-sectionally associated with worse later-life cognitive and behavioural symptoms.
Method Data are from the Canadian Platform for Research Online to Investigate Health, Quality of Life, Cognition, Behaviour, Function, and Caregiving in Aging (CAN-PROTECT). Measures included the Childhood Trauma Screener (CTS-5), neuropsychological testing, Everyday Cognition (ECog)-II scale, and MBI Checklist (MBI-C). Linear regressions modelled associations between ACEs severity and neuropsychological test scores. Multivariable negative binomial regressions (zero-inflated, if appropriate) modelled associations between ACEs severity and ECog-II and MBI-C scores. All models controlled for age, sex, education, and ethnocultural origin. Clinical diagnoses of depression and/or anxiety were explored as covariates or mediators.
Results In adjusted analyses, higher ACEs scores were associated with worse performance on Trail-Making B (standardized b=0.10, q=0.003), Switching Stroop (b=-0.08, q=0.027), Paired Associates Learning (b=-0.08, q=0.049), and Digit Span (b=-0.08, q=0.029). Higher ACEs scores were also associated with higher ECog-II (b=1.08, q=0.029) and MBI-C (b=1.20, q<0.001) scores; these associations were neither mediated by affective symptoms (ECog p=0.16; MBI p=0.13) nor moderated by sex (ECog p=0.09; MBI p=0.46).
Conclusion Older adults with a history of more severe ACEs show greater cognitive and behavioural risk markers for dementia that cannot be explained by previous psychiatric history. Further research into ACEs as an early modifiable risk factor for dementia is warranted.
Competing Interest Statement
EES reported consulting (unpaid) for Alnylam Pharmaceuticals and Eli Lilly, and an advisory board (unpaid) for Eisai. ZI has served as an advisor/consultant to CADTH, EISAI, Lilly, Lundbeck/Otsuka, Novo Nordisk, and Roche.
Funding Statement
CAN-PROTECT was supported by Gordie Howe CARES. The funder did not influence study design, collection, analysis, interpretation, writing, or decision to submit for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Conjoint Health Research Ethics Board at the University of Calgary Ethics provided approval for CAN-PROTECT (REB21-1065).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
